Acura Pharmaceuticals Gross Margin 2012-2021 | ACUR
Current and historical gross margin for Acura Pharmaceuticals (ACUR) over the last 10 years. The current gross profit margin for Acura Pharmaceuticals as of December 31, 2021 is %.
| Acura Pharmaceuticals Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2021-12-31 | $0.00B | $0.00B | 100.00% |
| 2021-09-30 | $0.00B | $0.00B | 100.00% |
| 2021-06-30 | $0.00B | $0.00B | 100.00% |
| 2021-03-31 | $0.00B | $0.00B | 100.00% |
| 2020-12-31 | $0.00B | $0.00B | 100.00% |
| 2020-09-30 | $0.00B | $0.00B | 100.00% |
| 2020-06-30 | $0.00B | $0.00B | 100.00% |
| 2020-03-31 | $0.00B | $0.00B | 100.00% |
| 2019-12-31 | $0.00B | $0.00B | 100.00% |
| 2019-09-30 | $0.00B | $0.00B | 100.00% |
| 2019-06-30 | $0.00B | 0 | 0.00% |
| 2019-03-31 | $0.00B | 0 | 0.00% |
| 2018-12-31 | $0.00B | 0 | 0.00% |
| 2018-09-30 | $0.00B | 0 | 0.00% |
| 2018-06-30 | $0.00B | 0 | 0.00% |
| 2018-03-31 | $0.00B | 0 | 0.00% |
| 2017-12-31 | $0.00B | $0.00B | 100.00% |
| 2017-09-30 | $0.01B | $0.01B | 100.00% |
| 2017-06-30 | $0.01B | $0.01B | 100.00% |
| 2017-03-31 | $0.01B | $0.01B | 100.00% |
| 2016-12-31 | $0.00B | $0.00B | 100.00% |
| 2016-09-30 | $0.00B | $0.00B | 100.00% |
| 2016-06-30 | $0.00B | $0.00B | 100.00% |
| 2016-03-31 | $0.00B | $0.00B | 100.00% |
| 2015-12-31 | $0.01B | $0.01B | 100.00% |
| 2015-09-30 | $0.01B | $0.01B | 83.33% |
| 2015-06-30 | $0.01B | $0.01B | 83.33% |
| 2015-03-31 | $0.01B | $0.01B | 83.33% |
| 2014-12-31 | $0.00B | 0 | 0.00% |
| 2014-09-30 | $0.00B | 0 | 0.00% |
| 2014-06-30 | $0.00B | 0 | 0.00% |
| 2014-03-31 | $0.00B | 0 | 0.00% |
| 2013-12-31 | $0.00B | 0 | 0.00% |
| 2011-12-31 | $0.02B | $0.02B | 100.00% |
| 2011-06-30 | $0.02B | $0.02B | 100.00% |
| 2011-03-31 | $0.00B | $0.00B | 100.00% |
| 2010-12-31 | $0.00B | $0.00B | 100.00% |
| 2010-09-30 | $0.00B | $0.00B | 100.00% |
| 2010-06-30 | $0.01B | $0.01B | 100.00% |
| 2010-03-31 | $0.01B | $0.01B | 100.00% |
| 2009-12-31 | $0.00B | $0.00B | 100.00% |
| 2009-09-30 | $0.01B | $0.01B | 100.00% |
| 2009-06-30 | $0.01B | $0.01B | 100.00% |
| 2009-03-31 | $0.03B | $0.03B | 100.00% |
| 2008-12-31 | $0.05B | $0.05B | 100.00% |
| 2004-06-30 | $0.00B | $-0.01B | -125.00% |
| 2004-03-31 | $0.01B | $-0.01B | -120.00% |
| 2003-12-31 | $0.01B | $-0.01B | -100.00% |
| 2003-09-30 | $0.01B | $0.00B | -66.67% |
| 2003-06-30 | $0.01B | $0.00B | -57.14% |
| 2003-03-31 | $0.01B | $0.00B | -50.00% |
| 2002-12-31 | $0.01B | $0.00B | -50.00% |
| 2002-09-30 | $0.01B | $-0.01B | -62.50% |
| 2002-06-30 | $0.01B | $0.00B | -18.18% |
| 2002-03-31 | $0.01B | $0.00B | -18.18% |
| 2001-12-31 | $0.02B | $0.00B | 11.76% |
| 2001-09-30 | $0.02B | $0.00B | 16.67% |
| 2001-06-30 | $0.02B | $0.00B | 5.56% |
| 2001-03-31 | $0.03B | $0.01B | 24.00% |
| 2000-12-31 | $0.02B | $0.00B | 10.00% |
| 2000-09-30 | $0.02B | $0.00B | 10.00% |
| 2000-06-30 | $0.02B | $0.00B | 5.88% |
| 2000-03-31 | $0.01B | $0.00B | -36.36% |
| 1999-12-31 | $0.01B | $0.00B | -27.27% |
| 1999-09-30 | $0.01B | $0.00B | -18.18% |
| 1999-06-30 | $0.01B | $0.00B | -18.18% |
| 1999-03-31 | $0.01B | $0.00B | -20.00% |
| 1998-12-31 | $0.01B | $0.00B | -33.33% |
| 1998-09-30 | $0.01B | $0.00B | -12.50% |
| 1998-06-30 | $0.01B | $0.00B | 25.00% |
| 1998-03-31 | $0.01B | $0.00B | 25.00% |
| 1997-12-31 | $0.01B | $0.00B | 22.22% |
| 1997-09-30 | $0.01B | $0.00B | -33.33% |
| 1997-06-30 | $0.01B | $-0.01B | -140.00% |
| 1997-03-31 | $0.01B | $-0.01B | -127.27% |
| 1996-12-31 | $0.01B | $-0.01B | -108.33% |
| 1996-09-30 | $0.01B | $0.00B | -14.29% |
| 1996-06-30 | $0.02B | $0.00B | -13.33% |
| 1996-03-31 | $0.02B | 0 | 0.00% |
| 1995-12-31 | $0.02B | $0.00B | 10.00% |
| 1995-09-30 | $0.02B | $-0.02B | -77.27% |
| 1995-06-30 | $0.02B | $-0.01B | -29.17% |
| 1995-03-31 | $0.03B | $0.00B | -8.00% |
| 1994-12-31 | $0.03B | $0.00B | 12.00% |
| 1994-09-30 | $0.03B | $0.02B | 80.77% |
| 1994-06-30 | $0.03B | $0.03B | 100.00% |
| 1994-03-31 | $0.03B | $0.03B | 100.00% |
| 1993-12-31 | $0.03B | $0.02B | 69.70% |
| 1993-09-30 | $0.04B | $0.03B | 75.00% |
| 1993-06-30 | $0.05B | $0.03B | 59.57% |
| 1993-03-31 | $0.05B | $0.03B | 47.17% |
| 1992-12-31 | $0.05B | $0.02B | 48.00% |
| 1992-06-30 | $0.03B | $0.01B | 25.00% |
| 1992-03-31 | $0.03B | $0.01B | 24.14% |
| 1991-09-30 | $0.03B | $0.01B | 23.53% |
| 1991-06-30 | $0.03B | $0.01B | 25.81% |
| 1991-03-31 | $0.03B | $0.01B | 27.59% |
| 1990-12-31 | $0.03B | $0.01B | 29.63% |
| 1990-09-30 | $0.03B | $0.01B | 28.00% |
| 1990-06-30 | $0.02B | $0.01B | 29.17% |
| 1990-03-31 | $0.02B | $0.01B | 31.82% |
| 1989-12-31 | $0.02B | $0.01B | 33.33% |
| 1989-09-30 | $0.02B | $0.01B | 40.00% |
| 1989-06-30 | $0.02B | $0.01B | 36.84% |
| 1989-03-31 | $0.02B | $0.01B | 33.33% |
| 1988-12-31 | $0.02B | $0.01B | 29.41% |
| 1988-09-30 | $0.01B | $0.00B | 23.08% |
| 1988-06-30 | $0.01B | $0.00B | 25.00% |
| 1988-03-31 | $0.01B | $0.00B | 30.77% |
| 1987-12-31 | $0.01B | $0.00B | 33.33% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Halsey Drug Company, Inc. is engaged in the manufacture, sale and distribution of generic drugs. A generic drug is the chemical and therapeutic equivalent of a brand-name drug for which patent protection has expired. The company sells its generic drug products under its Halsey label and under private-label arrangements with drugstore chains and drug wholesalers. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |